Detailed Narrative
Q3 FY25 Financial Performance Overview
Orchid Pharma reported a total income of INR227 crores and an EBITDA of INR37 crores for Q3 FY25. For the first nine months of FY25, total income grew by 15% year-on-year to INR710 crores, while EBITDA improved significantly from INR99 crores to INR115 crores. Net profit (PAT) for the nine-month period saw a 26% increase, reaching INR78 crores compared to INR62 crores in the previous year. Despite overall volumes increasing by over 20%, price corrections in a few major products muted the total sales number, as the company prioritized maintaining healthy margins.
Strategic Projects: 7ACA and Cefiderocol Updates
The 7ACA project, crucial for API self-reliance, is advancing with water trials expected by April '26 and commissioning by Q1 FY26. The budgeted spend for this project is INR600 crores, with INR80 crores already invested. Management anticipates a return on this investment within three years. The Cefiderocol project is also under construction, with commissioning targeted for November-December '26, pending drug approval in India.
Exblifep (Enmetazobactam) and AMS Division Traction
Domestically, Exblifep (Cefepime and Enmetazobactam) is performing as per initial expectations, leveraging a partnership with Cipla for market penetration. The Orchid AMS division, a new B2C business segment, is currently an investment phase, incurring an EBITDA drag of approximately INR6 crores over nine months. Management expects this division to become EBITDA accretive after another year or so, as it builds relationships with doctors and hospitals and expands its portfolio of 25-30 injectable products.
Regulatory Milestones and US Market Challenges
Orchid Pharma successfully received the EU GMP audit certificate in October '24, incurring a one-time📎 expense of INR3 crores for compliance readiness. Regarding the US market, the company is awaiting progress on a possible partnership for Enmetazobactam by Allecra, noting that the delay is a 'cause for concern' due to poor communication and lack of control. For its Ceftazidime filing in the US, the company is on track to refile in the next quarter after addressing RTR observations.
Pricing Environment and Margin Strategy
The company experienced price corrections in its top three products, influenced by Pen-G pricing and competition from China. Orchid Pharma's strategy is to maintain healthy gross margins, targeting 40% plus or minus 2% in the near term, even if it means not opting for higher volumes at reduced prices. Management aims for an EBITDA margin expansion of approximately 100 basis points every year, driven by increasing volumes and productivity enhancements. The company also noted that it holds INR194 crores in cash, earning around 7% interest, and expects no tax liability for the next 4-5 years due to INR790 crores in carry-forward losses.
Market Opportunities and Future Outlook
Orchid Pharma sees significant long-term potential, aiming for a 20% CAGR looking back three years from today. The company is preparing to file for generic Zavicefta in European markets, with an estimated ex-US market size of $500 million, of which Europe could constitute one-third. While acknowledging the risk of dumping from China in the 7ACA market, management believes the PLI scheme, GST benefits, and custom duties will provide a significant cushion. The company remains committed to operational excellence and innovation for future growth.